INS018-055 (ISM001-055, TNIK&MAP4K4-IN-2, compound 112) is an inhibitor of TNIK and MAP4K4. It exhibits an IC50 values of 12-120 nM on TNIK.

Tunlametinib (HL-085) is a highly selective and oral inhibitor of MEK1/2 with an IC50 of 1.9 nM for MEK1, with the potential to treat RAS/RAF mutant cancers. It also induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in a dose-dependent manner. It also exhibits antitumor activity in patients with advanced NRAS-mutant melanoma.

Tunlametinib (HL-085) is a highly selective and oral inhibitor of MEK1/2 with an IC50 of 1.9 nM for MEK1, with the potential to treat RAS/RAF mutant cancers. It also induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in a dose-dependent manner. It also exhibits antitumor activity in patients with advanced NRAS-mutant melanoma.

Tunlametinib (HL-085) is a highly selective and oral inhibitor of MEK1/2 with an IC50 of 1.9 nM for MEK1, with the potential to treat RAS/RAF mutant cancers. It also induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in a dose-dependent manner. It also exhibits antitumor activity in patients with advanced NRAS-mutant melanoma.

Tunlametinib (HL-085) is a highly selective and oral inhibitor of MEK1/2 with an IC50 of 1.9 nM for MEK1, with the potential to treat RAS/RAF mutant cancers. It also induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in a dose-dependent manner. It also exhibits antitumor activity in patients with advanced NRAS-mutant melanoma.

ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.

ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.

ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.

ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.

NT-0796 is a brain-penetrant and highly potent inhibitor of NLRP3 Inflammasome with a potential for treating neuroinflammatory disorders. It inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM.